Nilofer Saba Azad, MD

home / authors / nilofer-saba-azad-md

Articles

Nilofer S​aba Azad, MD, of Johns Hopkins ​University School of Medicine

Dr. Azad on Selecting Between Regorafenib and TAS-102 in CRC

Nilofer Saba Azad, MD
October 30th 2020

Nilofer S​aba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.

Read More

Nilofer S​aba Azad, MD, of Johns Hopkins Medicine

Dr. Azad on Third-Line Treatment Options in CRC

Nilofer Saba Azad, MD
October 29th 2020

Nilofer S​aba Azad, MD, discusses third-line treatment options for patients with colorectal cancer.

Read More

Nilofer S​aba Azad, MD

Dr. Azad on Future Research Efforts in CRC

Nilofer Saba Azad, MD
October 21st 2020

Nilofer S​aba Azad, MD, discusses future research efforts in colorectal cancer.

Read More

Nilofer S​aba Azad, MD

Dr. Azad on the Importance of Germline Testing in CRC

Nilofer Saba Azad, MD
October 19th 2020

Nilofer S​aba Azad, MD, discusses the significance of germline testing in colorectal cancer.

Read More

Nilofer S​aba Azad, MD

Dr. Azad on Treatment Considerations in Right- Versus Left-Sided CRC

Nilofer Saba Azad, MD
October 16th 2020

Nilofer S​aba Azad, MD, discusses treatment considerations in right- versus left-sided colorectal cancer.

Read More

Nilofer S​aba Azad, MD

Dr. Azad on Remaining Challenges in CRC

Nilofer Saba Azad, MD
October 15th 2020

Nilofer S​aba Azad, MD, discusses remaining challenges in colorectal cancer.

Read More

Latest Updated Articles

Alexis LeVee, MD
Published: May 14th 2025 | Updated: May 30th 2025
Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting
Arielle Heeke, MD
Published: May 2nd 2025 | Updated: May 6th 2025
Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Published: March 10th 2025 | Updated: April 25th 2025
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Núria Agustí Garcia, MD
Published: April 21st 2025 | Updated: April 23rd 2025
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer